Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
57°
Clear
Site search
Search
Menu
Subscribe
Home
News
Local News
Sports
Obituaries
Photos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Explore the Sheyenne
Best of 2023
Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Neogenomics Inc
(NQ:
NEO
)
16.52
+0.10 (+0.61%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 30, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Neogenomics Inc
< Previous
1
2
3
4
5
6
Next >
NeoGenomics to Participate Virtually in Multiple Upcoming Institutional Investor Conferences
February 08, 2022
FT. MYERS, FL / ACCESSWIRE / February 8, 2022 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, today...
From
NeoGenomics, Inc.
Via
AccessWire
NeoGenomics Schedules its Fourth Quarter and Full Year 2021 Earnings Release for February 23, 2022
February 02, 2022
FT MYERS, FL / ACCESSWIRE / February 2, 2022 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing and global contract research services, announced today that it plans...
From
NeoGenomics, Inc.
Via
AccessWire
NeoGenomics First to Partner with Biomarker Collaborative and Deliver Patient Resources Along with Oncology Testing Results
January 24, 2022
The partnership makes it possible for patients with specific biomarkers to get early support FT. MYERS, FL / ACCESSWIRE / January 24, 2022 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of...
From
NeoGenomics, Inc.
Via
AccessWire
NeoGenomics Announces RaDaR(TM) Assay Receives CE Mark and is Submitted for US Reimbursement via the MolDX Program
January 11, 2022
FT. MYERS, FL / ACCESSWIRE / January 11, 2022 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, today...
From
NeoGenomics, Inc.
Via
AccessWire
New Developments in Fight Against Blood Cancers, in Leadup to US$17.1 Billion Market by 2024
January 10, 2022
FN Media Group Presents USA News Group News Commentary Vancouver, BC –January 10, 2021 – USA News Group – Nearly 10% of the estimated ~1.9 million new cancer cases in the USA will be diagnosed as...
Via
FinancialNewsMedia
NeoGenomics Appoints David Eberhard MD, PhD as Chief Medical Officer of Inivata Liquid Biopsy Subsidiary
December 13, 2021
FT MYERS, FL / ACCESSWIRE / December 13, 2021 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, today...
From
NeoGenomics, Inc.
Via
AccessWire
Topics
Regulatory Compliance
Exposures
COVID-19
Legal
Product Safety
NeoGenomics to Leverage Thermo Fisher Scientific’s Ion Torrent Genexus System in Upcoming Phase 1 Study for Myeloid Cancers
December 10, 2021
FT. MYERS, FL / ACCESSWIRE / December 10, 2021 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, announced...
From
NeoGenomics, Inc.
Via
AccessWire
Topics
Regulatory Compliance
Exposures
COVID-19
Legal
Regulatory
NeoGenomics To Participate In The Stephens Annual Investment Conference 2021
November 30, 2021
FT. MYERS, FL / ACCESSWIRE / November 30, 2021 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, today...
From
NeoGenomics, Inc.
Via
AccessWire
Topics
Regulatory Compliance
Exposures
COVID-19
Legal
Regulatory
NASDAQ: NEO Shareholder Notice: Investigation over Potential Wrongdoing at NeoGenomics, Inc.
November 29, 2021
San Diego, CA -- (SBWIRE) -- 11/29/2021 -- An investigation on behalf of investors in NeoGenomics, Inc. (NASDAQ: NEO) shares over potential wrongdoing at NeoGenomics, Inc. was announced.
Via
SBWire
Exposures
COVID-19
NASDAQ:NEO Investor Notice: Investigation over Possible Securities Laws Violations by NeoGenomics, Inc.
November 10, 2021
San Diego, CA -- (SBWIRE) -- 11/10/2021 -- NeoGenomics, Inc. is under investigation concerning possible violations of securities laws in connection with certain financial statements.
Via
SBWire
Exposures
COVID-19
NeoGenomics Appoints Dave Daly to Its Board of Directors
November 10, 2021
FT. MYERS, FL / ACCESSWIRE / November 10, 2021 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, has...
From
NeoGenomics, Inc.
Via
AccessWire
Topics
Regulatory Compliance
Exposures
COVID-19
Legal
Regulatory
NeoGenomics Reports Revenue of $121 Million in the Third Quarter
November 04, 2021
Third-Quarter 2021 Results and Highlights: - Consolidated revenue of $121 million, comprised of Clinical Services revenue of $102 million and Pharma Services revenue of $19 million - Consolidated...
From
NeoGenomics, Inc.
Via
AccessWire
Topics
Regulatory Compliance
Retirement
Exposures
COVID-19
Legal
Pension
NeoGenomics Announces Leadership Team Transition
November 04, 2021
FT. MYERS, FL / ACCESSWIRE / November 4, 2021 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, announced...
From
NeoGenomics, Inc.
Via
AccessWire
Topics
Regulatory Compliance
Exposures
COVID-19
Legal
Regulatory
NeoGenomics' Liquid Biopsy Subsidiary Inivata Announces Clinical Collaboration With Princess Margaret Cancer Center for the Use of Its Liquid Biopsy Assays
October 19, 2021
Two clinical studies including interventional RaDaR™ study FT. MYERS, FL / ACCESSWIRE / October 19, 2021 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services...
From
NeoGenomics, Inc.
Via
AccessWire
Topics
Regulatory Compliance
Exposures
COVID-19
Legal
Product Safety
NeoGenomics Schedules its Third Quarter 2021, Earnings Release for November 4, 2021
October 13, 2021
FT. MYERS, FL / ACCESSWIRE / October 13, 2021 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing and global contract research services, announced today that it plans...
From
NeoGenomics, Inc.
Via
AccessWire
Topics
Regulatory Compliance
Exposures
COVID-19
Legal
Regulatory
NeoGenomics Announces Board of Directors' Transition
October 12, 2021
Appoints Lead Independent Director Lynn Tetrault as Non-Executive Chair. Douglas VanOort steps-down as Executive Chairman and will retire from the Board of Directors before the end of the year FT....
From
NeoGenomics, Inc.
Via
AccessWire
Topics
Regulatory Compliance
Retirement
Exposures
COVID-19
Legal
Pension
NeoGenomics' Liquid Biopsy Subsidiary Inivata and Collaborators to Present Data that Further Validate the Application of its RaDaR(TM) MRD and InVisionFirst(R)-Lung Assays at the ESMO Congress 2021
September 09, 2021
FT MYERS, FL / ACCESSWIRE / September 9, 2021 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, today...
From
NeoGenomics, Inc.
Via
AccessWire
Topics
Regulatory Compliance
Exposures
COVID-19
Legal
Product Safety
NeoGenomics to Participate in the Morgan Stanley 19th Annual Global Healthcare Conference
September 01, 2021
FT. MYERS, FL / ACCESSWIRE / September 1, 2021 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, today...
From
NeoGenomics, Inc.
Via
AccessWire
Topics
Regulatory Compliance
Exposures
COVID-19
Legal
Regulatory
NeoGenomics Reports 40% Revenue Growth to $122 Million in the Second Quarter
August 06, 2021
Second-Quarter 2021 Results and Highlights: - Consolidated revenue increased 40% to $122 million - Clinical Services revenue increased 37% to $101 million - Pharma Services revenue increased 55% to $20...
From
NeoGenomics, Inc.
Via
AccessWire
Topics
Regulatory Compliance
Retirement
Exposures
COVID-19
Legal
Pension
NeoGenomics Schedules its Second Quarter 2021 Earnings Release for August 6, 2021
July 14, 2021
FT. MYERS, FL / ACCESSWIRE / July 14, 2021 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing and global contract research services, announced today that it plans to...
From
NeoGenomics, Inc.
Via
AccessWire
Topics
Regulatory Compliance
Exposures
COVID-19
Legal
Regulatory
NeoGenomics Completes Inivata Acquisition - Combining Best-In-Class Liquid Biopsy Technology with Leading Community Oncology Platform
June 18, 2021
- Acquisition establishes NeoGenomics as a technology leader in the minimal residual disease (MRD) testing market FT. MYERS, FL / ACCESSWIRE / June 18, 2021 / NeoGenomics, Inc. (NASDAQ:NEO), a leading...
From
NeoGenomics, Inc.
Via
AccessWire
Topics
Regulatory Compliance
Exposures
COVID-19
Legal
Regulatory
NeoGenomics To Participate Virtually In Multiple Upcoming Institutional Investor Conferences
May 27, 2021
FT MYERS, FL / ACCESSWIRE / May 27, 2021 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, today announced...
From
NeoGenomics, Inc.
Via
AccessWire
Topics
Regulatory Compliance
Exposures
COVID-19
Legal
Regulatory
NeoGenomics To Participate In The Bank of America 2021 Health Care Conference
May 10, 2021
FT. MYERS, FL / ACCESSSWIRE / May 10, 2021 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, today...
From
NeoGenomics, Inc.
Via
AccessWire
Topics
Regulatory Compliance
Exposures
COVID-19
Legal
Regulatory
NeoGenomics Reports 9% Revenue Growth to $116 Million in the First Quarter
May 05, 2021
First-Quarter 2021 Results and Highlights: - Consolidated revenue increased 9% to $116 million - Clinical Services revenue increased 4% to $96 million - Pharma Services revenue increased 46% to $19...
From
NeoGenomics, Inc.
Via
AccessWire
Topics
Regulatory Compliance
Exposures
COVID-19
Legal
Regulatory
NeoGenomics to Acquire Inivata - Combining Best-In-Class Liquid Biopsy Technology with Leading Community Oncology Platform
May 05, 2021
Establishes NeoGenomics as a technology leader in the minimal residual disease (MRD) testing market NeoGenomics exercises option struck in May 2020 to purchase remaining equity stake for $390 million...
From
NeoGenomics, Inc.
Via
AccessWire
Topics
Regulatory Compliance
Exposures
COVID-19
Legal
Product Safety
NeoGenomics Announces the Launch of Biomarker Assist KRAS Single Gene Testing (SGT) Program for Advanced or Metastatic (Stage IV) Non-Small Cell Lung Cancer Patients
April 19, 2021
SGT Program will provide KRAS G12C testing to eligible patients at no cost, regardless of insurance type. FT. MYERS, FL / ACCESSWIRE / April 19, 2021 / NeoGenomics, Inc. (NASDAQ:NEO), a leading...
From
NeoGenomics, Inc.
Via
AccessWire
Topics
Regulatory Compliance
Exposures
COVID-19
Legal
Regulatory
NeoGenomics to Participate in the 20th Annual Needham Virtual Healthcare Conference
April 13, 2021
FT. MYERS, FL / ACCESSWIRE / April 13, 2021 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, today...
From
NeoGenomics, Inc.
Via
AccessWire
Topics
Regulatory Compliance
Exposures
COVID-19
Legal
Regulatory
NeoGenomics Schedules its First Quarter 2021 Earnings Release for May 5, 2021
April 07, 2021
FT MYERS, FL / ACCESSWIRE / April 7, 2021 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing and global contract research services, announced today that it plans to...
From
NeoGenomics, Inc.
Via
AccessWire
Topics
Regulatory Compliance
Exposures
COVID-19
Legal
Regulatory
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.